Covis Pharma is a specialty manufacturer of therapeutic solutions for patients with life-threatening conditions and chronic illnesses, ranging from ALS to heart failure.
Covis selected Verify Brand, a cross-industry, serialization and authentication company, based on the provider’s experience with virtual pharmaceutical manufacturers. Covis also found value in leveraging Verify Brand’s cloud-based user-friendly software, the Verify Platform, and its ongoing customer support.
“Even though the FDA has pushed its DSCSA enforcement back a year, it’s crucial that pharmaceutical companies continue to make their software selections quickly, but without sacrificing quality,” said Verify Brand CEO, Michael Howe.
With Verify Brand’s SWIFT serialization implementation process, Covis Pharma will be able to implement necessary DSCSA compliance components from the discovery stage to solution implementation and validation. The Verify Platform’s standards-based EPCIS software is already integrated with much of Covis’ supply chain partner network, leading toward global connectivity and enhanced supply chain visibility, and providing value beyond the U.S.-based DSCSA compliance regulations.
As Covis Pharma achieves its compliance objectives, additional platform functionality enables the pharma manufacturer to assess its business processes through robust real-time reporting and advanced supply chain analytics gleaned from the serialization data it captures. Covis recognizes that visibility and transparency within its supply chain network is key to obtaining end-to-end efficiencies and reducing total costs.
